1. Home
  2. Labeler Index
  3. Amgen Inc
  4. 55513-670
  5. Product Images: Avsola

Product Images Avsola

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Avsola NDC 55513-670 by Amgen Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1: Kaplan Meier estimate of the proportion of patients who had not lost response through Week 54 - avsola 01

Figure 1: Kaplan Meier estimate of the proportion of patients who had not lost response through Week 54 - avsola 01

The text appears to be a table or chart comparing the percentage of patients who did not lose response to different treatments. Infliimab at 10 mg/kg had a statistically significant difference compared to the placebo. However, the percentage for Infliimab at 5 mg/kg is not available or unclear. The table shows data for different study weeks and maintenance treatments.*

Figure 2: Life table estimates of the proportion of patients who had not lost fistula response through Week 54 - avsola 02

Figure 2: Life table estimates of the proportion of patients who had not lost fistula response through Week 54 - avsola 02

This appears to be a graph showing the percentage of patients who had not lost response to a treatment compared to a placebo maintenance. The study was conducted with infliximab at a dosage of 5mg/kg, and the results showed a significant difference compared to the placebo maintenance group. The graph displays the study week and the percentage of patients who had not lost response over time.*

Figure 3: Proportion of patients achieving ASAS 20 response - avsola 03

Figure 3: Proportion of patients achieving ASAS 20 response - avsola 03

This is a graph displaying the proportion of patients in percentage, with a range from 0 to 100 on the y-axis. There are two categories mentioned on the x-axis: placebo and Ifliximab 5mg/kg. However, there is not enough information to determine what the proportion of patients is referring to.*

Figure 4: Proportion of patients achieving ≥75% improvement in PASI from baseline through Week 50; patients randomized at Week 14 - avsola 04

Figure 4: Proportion of patients achieving ≥75% improvement in PASI from baseline through Week 50; patients randomized at Week 14 - avsola 04

PRINCIPAL DISPLAY PANELNDC 55513-670-01AVSOLA™(infliximab-axxq)For Injection 100 mg/vialAMGEN®100 mg/vialFor Intravenous infusion onlySingle-Dose Vial. Discard unused portion.Contents: Each carton contains one 100 mg AVSOLA Single-Dose Vial.ATTENTION: Dispense the enclosed Medication Guide to each patientReconstitute and Dilute before Intravenous Infusion. Infuse over at least 2 hours with an in-line filter.Protect from light.Dosage: See Prescribing Information.Rx Only - avsola 05

PRINCIPAL DISPLAY PANELNDC 55513-670-01AVSOLA™(infliximab-axxq)For Injection 100 mg/vialAMGEN®100 mg/vialFor Intravenous infusion onlySingle-Dose Vial. Discard unused portion.Contents: Each carton contains one 100 mg AVSOLA Single-Dose Vial.ATTENTION: Dispense the enclosed Medication Guide to each patientReconstitute and Dilute before Intravenous Infusion. Infuse over at least 2 hours with an in-line filter.Protect from light.Dosage: See Prescribing Information.Rx Only - avsola 05

AVSOLA is a medication given through intravenous infusion. It is available in 100mg/vial single dose vials, and any unused portion should be discarded. The medication should be reconstituted and diluted prior to infusion and infused over a minimum of 2 hours with an in-line filter. The prescribing information should be consulted for proper dosage. Patients should be given the enclosed medication guide. AVSOLA is NDC 55513-670-01.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.